Again, pregnant women with MAFLD and GDM were more likely to require insulin therapy (62.2% vs. 40.7%, p < 0.01), with a median peak insulin dosage of 10 units more than women without MAFLD [75]. This evidence concerns the gene INS and gestational diabetes.